Upgrade to SI Premium - Free Trial

Merck (MRK) PT Raised to $135 at BMO Capital

February 4, 2026 5:43 AM
BMO Capital analyst Evan David Seigerman raised the price target on Merck (NYSE: MRK) to $135.00 (from $130.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles